Professor Richard Scolyer, a pioneering melanoma researcher and former Australian of the Year, died Sunday night [1].

Scolyer was a global leader in cancer research whose work fundamentally changed the treatment of melanoma. His death marks the loss of a scientist who spent his final years documenting his own struggle with cancer to aid others.

He was 59 years old [1]. Scolyer died on June 8, 2026 [1], following complications from an aggressive brain tumour that was diagnosed three years earlier [2].

In a final public message, Scolyer urged Australians to "be brave, be bold" and to pursue their dreams with humility, love, and compassion [1]. His family and colleagues remembered him as a man dedicated to both his patients and his research.

Charles Nicholl, the brother-in-law of the professor, said he was "talented, passionate, selfless and loyal" [1].

A family spokesperson said Scolyer wanted cancer patients to know they weren't alone [3]. This commitment to patient visibility continued even as his own health declined, a trajectory that mirrored his professional dedication to improving survival rates for those with advanced skin cancers.

Scolyer's legacy includes his tenure as Australian of the Year, where he advocated for scientific literacy and public health. His work in immunotherapy helped transform melanoma from a largely fatal diagnosis into a manageable or curable condition for many patients worldwide [2].

“Pursue your dreams and passion with humility, love and compassion.”

The death of Professor Richard Scolyer removes a primary figure in the global effort to treat melanoma. Because he spent his final three years publicly sharing his experience as a patient while remaining a lead researcher, his case provides a rare, documented intersection of clinical expertise and patient experience that may influence future palliative and oncological care.